What happened.

XRP Ledger is retrying an amendment designed to let banks split payment and compliance duties. The retry follows reporting that a critical signer-related flaw was fixed before mainnet.

The record identifies the issue as a disclosed signer gap. It does not provide technical detail on the repair, activation timing, or how the amendment will perform once used in production.

Why it matters.

The amendment is framed as bank-facing infrastructure: separating payment and compliance duties could be relevant to institutions evaluating how those functions are handled within the network.

For now, this is a protocol-development event rather than evidence of production adoption. The reported repair removes one pre-mainnet obstacle, but it does not establish that the wider operating stack is ready.

Important limit and next receipt.

Nodes, clients, wallets and explorers have not yet been exercised in production against the repaired amendment, according to the supplied record. That leaves interoperability and operational readiness unresolved.

Watch for amendment activation and subsequent evidence that those components operate correctly in production. Those receipts would provide a clearer view of whether the repair holds beyond the pre-mainnet setting.

What to watch

Amendment activation and evidence of production readiness across nodes, clients, wallets and explorers.

Sources and limits

Upstream references and independent checks

Digest dated 2026-09-23 · upstream model sonnet. Direct links are matched to all 2 upstream source IDs.

  1. 1
    XRP Ledger retries upgrade that lets banks split payment and compliance dutiesDirect upstream source · 987257c111a2e15b2f6a5987e564229d999e1feb
  2. 2
    XRPL fixes critical pre-mainnet flaw, but client apps remain at riskDirect upstream source · bac496ff5c3d916fc8089f8f7b9cb5e1158c3407

This Research brief was generated by Terra from a dated upstream research digest. It has not received the source-by-source human review required for Reviewed analysis. Material limit: The evidence is limited to two approved reporting items, with no direct primary-source material or production-validation results supplied.